Joel Beatty

Stock Analyst at Baird

(4.60)
# 217
Out of 5,241 analysts
215
Total ratings
52.33%
Success rate
34.45%
Average return

Stocks Rated by Joel Beatty

Alkermes
May 13, 2026
Maintains: Outperform
Price Target: $45$48
Current: $37.48
Upside: +28.07%
Axsome Therapeutics
May 5, 2026
Maintains: Outperform
Price Target: $241$246
Current: $227.72
Upside: +8.03%
e.l.f. Beauty
Apr 28, 2026
Maintains: Outperform
Price Target: $115$90
Current: $56.43
Upside: +59.49%
Denali Therapeutics
Apr 7, 2026
Maintains: Outperform
Price Target: $32$34
Current: $18.62
Upside: +82.60%
Immutep
Mar 13, 2026
Downgrades: Neutral
Price Target: $7$1
Current: $0.52
Upside: +92.42%
Dianthus Therapeutics
Mar 10, 2026
Maintains: Outperform
Price Target: $67$132
Current: $86.16
Upside: +53.20%
Contineum Therapeutics
Mar 6, 2026
Maintains: Outperform
Price Target: $14$20
Current: $13.72
Upside: +45.77%
Praxis Precision Medicines
Feb 20, 2026
Maintains: Outperform
Price Target: $275$433
Current: $342.58
Upside: +26.39%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $72$47
Current: $25.00
Upside: +88.00%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160$209
Current: $228.77
Upside: -8.64%
Maintains: Outperform
Price Target: $10$19
Current: $13.29
Upside: +43.02%
Maintains: Outperform
Price Target: $10$7
Current: $3.58
Upside: +95.53%
Maintains: Outperform
Price Target: $4$6
Current: $2.62
Upside: +129.01%
Maintains: Neutral
Price Target: $7$9
Current: $32.68
Upside: -72.46%
Maintains: Outperform
Price Target: $28$31
Current: $21.40
Upside: +44.86%
Downgrades: Neutral
Price Target: $38$24
Current: $29.82
Upside: -19.52%
Upgrades: Outperform
Price Target: $680
Current: $799.32
Upside: -14.93%
Maintains: Outperform
Price Target: $70$66
Current: $71.47
Upside: -7.65%
Maintains: Outperform
Price Target: $28$32
Current: $31.18
Upside: +2.63%
Initiates: Outperform
Price Target: $75
Current: $77.47
Upside: -3.19%
Maintains: Neutral
Price Target: $72$65
Current: $51.81
Upside: +25.46%
Maintains: Outperform
Price Target: $540$240
Current: $0.19
Upside: +129,210.34%
Downgrades: Neutral
Price Target: $4.5
Current: $1.29
Upside: +248.84%
Maintains: Outperform
Price Target: $24$25
Current: $15.86
Upside: +57.68%
Maintains: Outperform
Price Target: $32$28
Current: $20.23
Upside: +38.41%
Initiates: Outperform
Price Target: $16
Current: $1.55
Upside: +932.26%
Maintains: Outperform
Price Target: $4$1.25
Current: $1.36
Upside: -8.09%
Initiates: Outperform
Price Target: $44
Current: $1.15
Upside: +3,726.09%
Maintains: Outperform
Price Target: $60$58
Current: $76.67
Upside: -24.35%
Maintains: Outperform
Price Target: $18$24
Current: $28.21
Upside: -14.92%
Downgrades: Underperform
Price Target: $18
Current: $7.47
Upside: +140.96%
Maintains: Outperform
Price Target: $9$6
Current: $1.67
Upside: +259.28%
Upgrades: Neutral
Price Target: $36$28
Current: $8.79
Upside: +218.54%
Downgrades: Neutral
Price Target: $170$175
Current: $286.98
Upside: -39.02%
Downgrades: Neutral
Price Target: $14
Current: $6.28
Upside: +122.93%
Downgrades: Neutral
Price Target: $108
Current: $17.55
Upside: +515.38%
Maintains: Buy
Price Target: $80$78
Current: $74.23
Upside: +5.08%
Maintains: Buy
Price Target: $140$100
Current: $19.65
Upside: +408.91%
Maintains: Buy
Price Target: $480$120
Current: $14.51
Upside: +727.30%
Maintains: Buy
Price Target: $480$450
Current: $3.94
Upside: +11,321.32%
Upgrades: Buy
Price Target: n/a
Current: $3.12
Upside: -
Maintains: Buy
Price Target: $19$15
Current: $9.06
Upside: +65.56%
Upgrades: Neutral
Price Target: $14$11
Current: $21.71
Upside: -51.64%
Maintains: Buy
Price Target: $15$19
Current: $9.22
Upside: +106.07%